Patents Issued in June 12, 2018
  • Patent number: 9994610
    Abstract: The present invention relates to a method for the separation of antibodies, specifically antibodies having different degrees of fucosylation. The method is based on binding affinity of antibodies to Fc receptors. The invention further relates to the use of Fc receptors for the separation of antibodies having different degrees of fucosylation.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: June 12, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Anne Freimoser-Grundschober, Christiane Jaeger, Peter Sondermann, Pablo Umana
  • Patent number: 9994611
    Abstract: Methods for the improved purification of antibodies and other proteins from protein preparations including the steps of conditioning the protein preparation by contacting it with multivalent organic ions, then applying the conditioned preparation to an adsorptive chromatography medium.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: June 12, 2018
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Peter Stanley Gagnon, Tze Yang Lee
  • Patent number: 9994612
    Abstract: Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Shelly Pizarro, Ailen Sanchez, Charles H. Schmelzer
  • Patent number: 9994613
    Abstract: This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 12, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marion W. Wannamaker, Robert J. Davies
  • Patent number: 9994614
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: June 12, 2018
    Assignee: Naurex, Inc.
    Inventor: M. Amin Khan
  • Patent number: 9994615
    Abstract: A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: June 12, 2018
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Robert S. Langer, Daniel G. Anderson, Zhen Gu, Alex Arthur Aimetti
  • Patent number: 9994616
    Abstract: A peptide functioning as a c-Met agonist is described. A peptide complex comprising two or more peptides that bind to a c-Met protein and a linker that links the two or more peptides to one another is described. Such a peptide complex promotes autophosphorylation of the c-Met protein and induces cell growth.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: June 12, 2018
    Assignee: The University of Tokyo
    Inventors: Hiroaki Suga, Kenichiro Ito
  • Patent number: 9994617
    Abstract: The invention describes a method for selecting a polypeptide ligand having a desired level of specificity for a target, wherein the polypeptide ligand comprises a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, comprising (i) screening at least two different sets of polypeptide ligands against the target, and selecting one or more ligands from each library which interact with the target; (ii) comparing the activity of the selected ligands with one or more paralogues or orthologues of the target; and (iii) further selecting one or more ligands according to their activity towards said one or more paralogues or orthologues; wherein said two or more different sets of ligands differ in the length of the polypeptide loops formed on the molecular scaffold.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: June 12, 2018
    Assignee: BicycleRD Limited
    Inventors: John Tite, Edward Walker, Catherine Stace, Christian Heinis
  • Patent number: 9994618
    Abstract: Provided is a method of purifying human papillomavirus (HPV) L1 proteins with high purity and high efficiency. According to the purification method, a purification purity and yield of HPV L1 proteins can be considerably increased when heating/chilling is formed by treating a cell homogenate with a reducing agent. In addition, VLPs of the HPV L1 protein purified by the purification method have excellent antigenicity and immunogenicity.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: June 12, 2018
    Inventor: Hong-Jin Kim
  • Patent number: 9994619
    Abstract: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of herpes virus antigens, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provide herein are methods for generating an immune response against herpes virus using the vaccines that are provided.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 12, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B Weiner, Devon Shedlock
  • Patent number: 9994621
    Abstract: The present invention relates to novel DNA sequences encoding insecticidal Cry1 C proteins derived from Bacillus thuringiensis, and their use in plants to control insect pests. Also included herein are plant cells or plants comprising such genes and methods of making or using them, as well as plant cells or plants comprising a Cry1 C chimeric gene of the invention and at least one other chimeric gene, such as a chimeric gene encoding an insecticidal Cry1Ab protein, and methods of making or using such plant cells or plants.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: June 12, 2018
    Assignee: BAYER CROPSCIENCE N.V.
    Inventors: Veronique Gossele, Frank Meulewaeter, Bernadette Saey, Stefan Jansens
  • Patent number: 9994622
    Abstract: Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: June 12, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Normand Blais, Philippe Marc Helene Dehottay, Marianne Dewerchin, Philippe Goffin, Denis Martin
  • Patent number: 9994623
    Abstract: The invention relates to novel entomotoxic polypeptides of the family of albumins 1b in legumes. Said polypeptides can be especially used as insecticides.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: June 12, 2018
    Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON
    Inventors: Corinne Royer, Pedro Da Silva, Frédéric Gressent, Lamis Karaki, Yvan Rahbe
  • Patent number: 9994624
    Abstract: The present invention relates to vaccines comprising a ShK domain of a filarial nematode protein. These vaccines may be used for the prevention and/or treatment of filarial nematode infections. The invention also relates to novel proteins comprising a ShK domain of a filarial nematode protein and pharmaceutical compositions. The invention may be used for the prevention and/or treatment of filarial nematode infections in canine subjects, and also in human subjects.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: June 12, 2018
    Assignees: THE UNIVERSITY OF LIVERPOOL, EDINBURGH UNIVERSITY
    Inventors: Ben Makepeace, David Taylor, Simon Babayon, Stuart Armstrong, Mark Blaxter
  • Patent number: 9994625
    Abstract: Protein misfolding underpins several fatal neurodegenerative disorders. The application is directed to recombinant Hsp104 proteins comprising missense mutations aimed at correcting these events, and methods for expressing and delivering same.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: June 12, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James Shorter, Meredith E. Jackrel
  • Patent number: 9994626
    Abstract: The invention relates to a polypeptide capable of binding human complement component 5 (C5), said polypeptide comprising the amino acid sequence (SEQ ID NO: 296) [BM]-[L2]-QSX42X43LLX46EAKKLX52X53X54Q wherein [BM] is a C5 binding motif; [L2] is an interconnecting loop; X42 is selected from A and S; X43 is selected from N and E; X46 is selected from A, S and C; X52 is selected from E, N and S; X53 is selected from D, E and S, provided that X53 is not D when X52 is N; and X54 is selected from A and S.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: June 12, 2018
    Assignee: Swedish Orphan Biovitrum AB (publ)
    Inventors: Joakim Nilsson, Erik Nordling, Patrik Strömberg
  • Patent number: 9994627
    Abstract: The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an N-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: June 12, 2018
    Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.
    Inventors: Yeo-Wook Koh, Sang-Yong Lee, Cook-Hee Kim, Seung-Hui Lee, Ha-Na Kim, Su-Yon Kim, Jin-Hyun Seong, Yong-Hyun Cho
  • Patent number: 9994628
    Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to the patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 12, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 9994629
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: June 12, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Karuppiah Muthumani, Niranjan Sardesai, Seleeke Flingai
  • Patent number: 9994630
    Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: June 12, 2018
    Assignee: CANGENE CORPORATION
    Inventors: Jody Berry, Darrell Johnstone, Joyee Antony George, Bonnie Tighe
  • Patent number: 9994631
    Abstract: Diagnostics relating to C-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefore.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: June 12, 2018
    Assignee: UPSTREAM MEDICAL TECHNOLOGIES LIMITED
    Inventors: Christopher Joseph Pemberton, Arthur Mark Richards
  • Patent number: 9994632
    Abstract: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor through Ang2, and methods of using the same.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: June 12, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seok Kyun Kim, Sunghyun Kim, Sang Yeul Han, Seung Hyun Lee, Su Jin Kim, Yong In Kim, Hyung-Chan Kim, Kwang Hoon Lee, Hyo Seon Lee
  • Patent number: 9994633
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: June 12, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
  • Patent number: 9994634
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 12, 2018
    Assignee: ZYMOGENETICS, INC.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Patent number: 9994635
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: June 12, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • Patent number: 9994636
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: June 12, 2018
    Assignees: MedImmune Limited, Cambridge Enterprise Limited
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • Patent number: 9994637
    Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: June 12, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zeren Gao, Steven D. Levin, Janine M. Bilsborough, James W. West, Cameron S. Brandt, Eric M. Chadwick
  • Patent number: 9994638
    Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 12, 2018
    Inventors: Tse-Wen Chang, Hsing-Mao Chu, Chien-Jen Lin, Chun-Yu Lin
  • Patent number: 9994639
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumor growth.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: June 12, 2018
    Assignee: Ablynx N.V.
    Inventors: Francis Descamps, David Andre Baptiste Maussang-Detaille, Maarten Van Roy, Maria Gonzalez Pajuelo, Regorius Leurs, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
  • Patent number: 9994640
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 12, 2018
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9994641
    Abstract: Disclosed are a novel anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 6 and 7 that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C-terminal side.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: June 12, 2018
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Hiroyuki Sonoda, Hideto Morimoto, Yuri Koshimura, Masafumi Kinoshita, Haruna Takagi, Yoshiko Yoshii
  • Patent number: 9994642
    Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Craig Smith, Peter S. Chin
  • Patent number: 9994643
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
  • Patent number: 9994644
    Abstract: Antibodies specifically binding an epitope comprised in the ?-chain of c-Met, modifications, compositions and uses thereof are disclosed herein.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 12, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Shuxian Julin Wong, David Philip Lane
  • Patent number: 9994645
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: June 12, 2018
    Assignee: ESBATech—a Novartis Company LLC
    Inventor: Dominik Escher
  • Patent number: 9994646
    Abstract: The invention provides engineered protein complexes constructed using a coiled coil and/or a tether and methods for making, using, and purifying such complexes, such as multispecific antibodies or other multispecific Fc containing complexes.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Erin H. Christensen, Dan L. Eaton, Andrew C. Vendel, Bernd Wranik
  • Patent number: 9994647
    Abstract: The present invention relates to a A metal complex of formula 1 CyYMLjXn??(formula 1) wherein Cy is a cyclopentadienyl-type ligand; M is a metal of group 4; L is a neutral Lewis basic ligand wherein the number of said neutral ligands “j” is in the range of 0 to the amount that satisfies the 18-electron rule: X is an anionic ligand; n is an integer denoting the number of anionic ligands X and is 1 or 2, preferably is 2; Y is a cyclic amidine-containing ligand moiety represented by formula 2 wherein the amidine-containing ligand is covalently bonded to the metal M via the imine nitrogen atom N2; S is a —CH2— unit, and t is the integer number denoting the number of S and is in the range of 1-4, more preferably in the range of 1-2, most preferably is 1; Sub1 is an aliphatic cyclic or linear substituent comprising a group 14 atom through which Sub2 is bonded to the amine nitrogen atom N1; Sub2 is an optionally substituted C2 unit in which the 2 carbon atoms may be sp2 or sp3 hybridized.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: June 12, 2018
    Assignee: ARLANXEO NETHERLANDS B.V.
    Inventors: Van Gerardus Henricus Josephus Doremaele, Alexandra Berthoud, Victor Quiroga Norambuena, Leszek Rupnicki, Peter Karbaum
  • Patent number: 9994648
    Abstract: The present invention describes a metallocene catalyst based on a transition metal of group 4 or 5 of the periodic table, supported on a hybrid catalytic support provided with aliphatic organic groups, and a process for supporting metallocene on the hybrid catalytic support. The supported metallocene catalyst provides an ethylene polymer with broad or bimodal molecular weight distribution, in the presence of only one metallocene complex on the support.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: June 12, 2018
    Assignees: Braskem S.A., Universidade Federal do Rio Grande do Sul
    Inventors: Rodrigo Brambilla, Marcia Silva Lacerda Miranda, Joao Henrique Zimnoch dos Santos, Fernando Silveira
  • Patent number: 9994649
    Abstract: A method for recovering a hydrofluorocarbon, including: producing a wet fluoropolymer by suspension polymerization, solution polymerization, or bulk polymerization in the presence of a hydrofluorocarbon; vaporizing and discharging vaporizable substances including the hydrofluorocarbon by heating the wet fluoropolymer in a container; and transferring the discharged vaporizable substances to a cooling means to cool the substances.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: June 12, 2018
    Assignee: DAIKIN INDUSTRIES, LTD.
    Inventors: Yumi Zenke, Tadaharu Isaka, Ryouichi Fukagawa, Takeshi Shimono
  • Patent number: 9994650
    Abstract: A method for producing a hydrogenated petroleum resin by reacting dicyclopentadiene with a vinyl aromatic compound, subjecting the reaction product obtained by this reaction to thermal polymerization, and then hydrogenating the resulting product, including the following steps (A) to (C): (A) a preliminary reaction step of reacting a vinyl aromatic compound represented by the following Formula (1) (in the formula, R1 is a hydrogen atom or the like) with dicyclopentadiene under the condition that selectivity for a phenylnorbornene derivative, which is a reaction product and is represented by the following Formula (2) {in the formula, R1 has the same meaning as in the above Formula (1)}, is 90% or more to obtain a reaction liquid containing the phenylnorbornene derivative: (B) a polymerization step of heating the reaction liquid, which contains the phenylnorbornene derivative and is obtained in the preliminary reaction step (A), to a temperature of 240 to 300° C.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: June 12, 2018
    Assignee: MARUZEN PETROCHEMICAL CO., LTD.
    Inventors: Yoshikazu Iijima, Koichiro Kanai, Yasunori Hayashi, Takeshi Haruna
  • Patent number: 9994651
    Abstract: The object of the invention is a composition comprising (a) cross-linked polymers containing pending links and cross-links that are exchangeable by aldehyde-imine exchange reactions and/or by imine-imine exchange reactions, obtained by cross-linking of linear or branched polymers; and (b) free monofunctional aldehydes and/or free monofunctional Another object of the invention is preparation processes of such a composition and the uses of the composition. Another object of the invention is compositions for cross-linking linear or branched polymers and their use to form a composition comprising cross-linked polymers containing pending links and cross-links that are exchangeable by aldehyde-imine exchange reactions and/or by imine-imine exchange reactions. Finally, an object of the invention is the use of aldehyde to catalyze imine-imine metathesis reactions and imine-aldehyde exchange reactions.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: June 12, 2018
    Assignee: ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Ludwik Leibler, Renaud Nicolay, Max Rottger
  • Patent number: 9994652
    Abstract: Provided are a novel metallocene compound, a catalyst composition including the same, and a method of preparing a polyolefin using the same. The metallocene compound according to the present invention and the catalyst composition including the same may be used for the preparation of a polyolefin, may have excellent polymerization ability, and may produce a polyolefin having an ultra-high molecular weight. In particular, when the metallocene compound according to the present invention is employed, an olefin-based polymer having an ultra-high molecular weight may be polymerized because the metallocene compound shows high polymerization activity even when it is supported on a support.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: June 12, 2018
    Assignee: LG CHEM, LTD.
    Inventors: Jin Young Park, Yong Ho Lee, Kyung Jin Cho, Ki Soo Lee, Bog Ki Hong, Min Seok Cho, Dae Hwan Kim, Se Young Kim, Sung Min Lee, Chang Woan Han, Sung Ho Park
  • Patent number: 9994653
    Abstract: Provided are a novel metallocene compound, a catalyst composition including the same, and a method of preparing an olefin-based polymer using the same. The metallocene compound according to the present invention or the catalyst composition including the same may be used for the preparation of an olefin-based polymer, may have excellent polymerization ability, and may produce an olefin-based polymer having a high molecular weight. In particular, when the metallocene compound according to the present invention is employed, an olefin-based polymer having a high molecular weight may be polymerized because the metallocene compound shows high polymerization activity even when it is supported on a support and maintains high activity even in the presence of hydrogen because of its low hydrogen reactivity.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: June 12, 2018
    Assignee: LG CHEM, LTD.
    Inventors: Yong Ho Lee, Kyung Jin Cho, Jin Young Park, Ki Soo Lee, Min Seok Cho, Se Young Kim, Sung Min Lee, Chang Woan Han
  • Patent number: 9994654
    Abstract: The invention relates to a continuous process for the production of ultra-high molecular weight polyethylene with an Elongational Stress of at least 0.43 N/mm2. The polymerization of ethylene takes place in the presence of a catalyst and hydrogen. It is an advantage of the process according to the invention that the use of small amounts of hydrogen during the production of UHMWPE reduces reactor fouling. Furthermore, the process according to the invention results in longer run times in polymerization reactors, less cleaning cycles to remove reactor fouling and in less need for other anti-fouling agents or anti-static agents.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 12, 2018
    Assignee: SABIC GLOBAL TECHNOLOGIES B.V.
    Inventors: Nicolaas Hendrika Friederichs, Mark Vlaar, Tom Schoffelen, Matthijs Van Kessel
  • Patent number: 9994655
    Abstract: The invention relates to a resin mixture having a modified epoxy (meth)acrylate resin as the base resin, and optionally at least one reactive diluent, at least one stabilizer, and at least one accelerator, wherein the modified epoxy (meth)acrylate resin can be obtained by reacting organic compounds having epoxide groups with (meth)acrylic acid, and then by the partial esterification of the ?-hydroxyl-groups, the same formed during the reaction, with the anhydride of a saturated dicarboxylic acid, to reactive resin mortars containing the same, and to the use thereof for the purpose of chemical fastening, by means of which it is possible to manufacture products which are not subject to labeling requirements and which additionally provide high bond strength.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: June 12, 2018
    Assignee: HILTI AKTIENGESELLSCHAFT
    Inventors: Gerald Gaefke, Thomas Burgel, Michael Leitner
  • Patent number: 9994656
    Abstract: A process for polymerizing propylene in the presence of a polymerization catalyst by polymerizing propylene with a comonomer selected from the group of ethylene and C4-C10 alpha-olefins in two polymerization stages where the comonomer is present in at least one of the polymerization stages. The first polymerization stage is conducted in a loop reactor and the second polymerization stage in a gas phase reactor. The polymer produced in first polymerization stage has a higher melt flow rate and a lower content of comonomer units than the final polymer mixture. The process can be operated with a high throughput and catalyst productivity. The polymers are useful for making films.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: June 12, 2018
    Assignee: BOREALIS AG
    Inventors: Torvald Vestberg, Kauno Alastalo
  • Patent number: 9994657
    Abstract: This invention relates to a process to polymerize olefins comprising: i) contacting one or more olefins with a catalyst system comprising: 1) a support comprising an organoaluminum treated layered silicate and an inorganic oxide; and 2) a bisphenolate compound; and ii) obtaining olefin polymer having high molecular weight and layered silicate dispersed therein. Preferably the support is in the form of spheroidal particles.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: June 12, 2018
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Crisita Carmen H. Atienza, Matthew W. Holtcamp, Xuan Ye, Gregory S. Day, David A. Cano, Michelle E. Titone, Machteld M. W. Mertens, Gerardo J. Majano Sanchez
  • Patent number: 9994658
    Abstract: This invention relates to a process to polymerize olefins comprising: i) contacting one or more olefins with a catalyst system comprising: 1) a support comprising an organoaluminum treated layered silicate and an inorganic oxide; and 2) a bisphenolate compound; and ii) obtaining olefin polymer having high molecular weight and layered silicate dispersed therein. Preferably the support is in the form of spheroidal particles.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: June 12, 2018
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Crisita Carmen H. Atienza, Matthew W. Holtcamp, Xuan Ye, Gregory S. Day, David A. Cano, Machteld M. W. Mertens, Gerardo J. Majano Sanchez, Rohan A. Hule
  • Patent number: 9994659
    Abstract: A crosslinked metallocene-catalyzed polyethylene copolymer having a higher molecular weight (HMW) component and lower molecular weight (LMW) component wherein the HMW component is present in an amount of from about 10 wt. % to about 30 wt. % and wherein the LMW component is present in an amount of from about 70 wt. % to about 90 wt. %.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 12, 2018
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: Vivek Rohatgi, Yongwoo Inn, Ashish M. Sukhadia, Qing Yang, Paul J. DesLauriers
  • Patent number: 9994660
    Abstract: The (meth)acrylic acid-based copolymer of the present invention includes, as essential structural units: 16 mol % or more but 24 mol % or less of a structural unit (a) derived from a monomer represented by Formula (1): wherein R2 represents a hydrogen atom or a methyl group; and X and Y each independently represent a hydroxy group, a sulfonic acid group, or a sulfonic acid salt group, at least one of X and Y representing a sulfonic acid group or a sulfonic acid salt group; and 76 mol % or more but 84 mol % or less of a structural unit (b) derived from (meth)acrylic acid or a salt thereof, each based on 100 mol % of all the structural units derived from monomers, the copolymer comprising a main chain having a sulfonic acid group or a sulfonic acid salt group at at least one end thereof, the copolymer having a weight average molecular weight of 1000 to 18000.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: June 12, 2018
    Assignee: Nippon Shokubai Co., Ltd.
    Inventors: Masato Nakano, Yuki Sano